- Two new studies increase our understanding of the consequences of SARS-CoV-2 infection during pregnancy. One study in Molecular Psychology found that maternal COVID-19 increases the incidence of neurodevelopmental disorders in children. “Our findings support a model where the maternal COVID-19 infection changed the levels of CD4 proliferating T cells, leading to the alterations of astrocytes, endothelial cells, and excitatory neurons in offspring,” the study’s authors wrote. Another study in Cell found increased risk of fetal situs inversus, a congenital heart abnormality, after SARS-C0V-2 infection during the early weeks of pregnancy (4-6 weeks).
- More evidence has emerged that COVID-19 can trigger autoimmune diseases. A retrospective cohort study in JAMA Dermatology of nearly seven million people concluded that COVID-19 increased the risk and incidence of autoimmune and autoinflammatory connective tissue disorders, including Lupus, Rheumatoid Arthritis, and Sjögren’s. Severe COVID-19 and being unvaccinated increased the risk. “These findings suggest that long-term monitoring and management of patients is crucial after COVID-19, considering demographic factors, disease severity, and vaccination status, to mitigate these risks,” the study’s authors wrote.
- A Mount Sinai CoRe clinical trial has just started recruiting to test the fibrinolytic enzyme, Lumbrokinase. The trial is currently recruiting people with Long COVID, Myalgic Encephalomyelitis, and Lyme to test the brand Boluoke®’s supplement daily for six weeks at 300,000 functional units (FUs.) Read more about the study in our past reporting. The study is based in New York City; to inquire about enrolling contact: CoreResearch@mountsinai.org. You can find more clinical trials at LongCovidStudies.net.
Leave a Reply